Stocks Rebounding: A.P. Pharma, Inc. (OTC:APPA), Trina Solar Limited (ADR) (NYSE:TSL), Cytokinetics, Inc. (NASDAQ:CYTK)

Posted by Ryan Mandell April 24, 2013 0 Comment 717 views


Northern, WI 04/24/2013 (GDPInsider) –  A.P. Pharma, Inc. (OTC:APPA) opened trading at $0.32 and is presently up 9.38%. Trading range is $0.32 and 0.36 with a volume of 451.4K. The stock is recovering from the dip suffered when the FDA rejected approval for the company’s anti-nasseu drug. APPA is up 24.64% on its 52-week low but still down 60.79% on its 52-week high. The RSI of the stock is 32.51 and the stock is presently trading 35.80% below its 52-week low. EPS this year is expected to rise by 58.41% and no consensus has yet being made by analysts on a target price for APPA. The stock has a negative EPS of $0.10 and presently 50.17% of shares in the company are owned by institutions.

Is APPA a solid investment at these levels? Get must-have updates and insights right here.

Trina Solar Limited (ADR) (NYSE:TSL) opened the day’s trading at $4.33 and is up 3.01%. The trading range of the stock is presently $4.32 and $4.50 and volume is 477.09K. TSL is down 44.44% on its 52-week high but up 117.60% on its 52-week low. The stock is currently trading 6.65% above its 50-day moving average but a healthier 14.69% above its 20-day moving average. The company has an earnings call reporting date of May 20, 2013 and EPS this year is expected to fall by 602.14%. There are 78.92 million shares outstanding and 63.78% of shares are owned by institutions. The stock has an RSI of 61.23 and the technical chart has shown a northward slope since the start of April 2013.

 How Should Investors Trade TSL Now? Get exclusive insights in this free report!

Cytokinetics, Inc. (NASDAQ:CYTK) opened trading for the day at $1.37 and is presently trading down 5.84%. Volume in the stock is 478.98K and the trading range is $1.30 and $1.37. Cytokinetics is expected to report first quarter earnings on April 30 and many analysts have commented on the company’s prospects with its congestive heart failure drug, omecamtiv mecarbil. The company is presently conducting a phase III clinical study with the drug and analysts believe a successful trial and the commercialization of the drug could net as much as $300 million for Cytokinetics. Sales have risen quarter on quarter by 188.51% and the EPS this year is expected to rise by 46.45%.

How Should Investors Trade CYTK Now? Get the latest trends and data here.

 


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment